Loading ...

Followers

Cutaneous manifestations & Dermatologic care IN COVID-19

Cutaneous manifestations & Dermatologic care IN COVID-19

 

Cutaneous manifestations &
Dermatologic care IN COVID-19

 

cutaneous manifestations in covid-19 a new contribution cutaneous manifestations in covid-19 the experiences of barcelona and rome cutaneous manifestations in covid-19 a first perspective recalcati skin manifestation in covid 19 cutaneous manifestations of covid-19 a systematic review cutaneous manifestations of covid-19 a preliminary review cutaneous manifestations of covid-19 an evidence-based review the cutaneous manifestations of covid-19 a review of emerging literature cutaneous manifestation of covid-19 in images a case report emerging skin manifestations of covid 19 cutaneous manifestations in covid-19 family cluster of urticarial rash cutaneous manifestations in covid-19 lessons learned from current evidence what rash is associated with covid

A variety of cutaneous manifestations have been reported in ptns with confirmed diagnosis or suspected severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease that may include a morbilliform rash; urticaria; pernio-like, acral lesions; livedo-like, vascular lesions; & vesicular, varicella-like eruptions. A severe multisystem inflammatory syndrome with muco-cutaneous, systemic, lab profile, and multiple imaging of atypical, severe Kawasaki disease has also been observed in children & adolescent COVID-19 infection. Skin injury, mechanical/friction dermatitis, & hand irritant contact dermatitis owing to personal protective equipment (PPE) & hand hygiene precautions have been observed in most of the health care stafs involved in the care of ptns with COVID-19 infection. The use of a barrier film or dressings at pressure points of PPE, in addition to the  frequent use of emollients after hand washing may help reducing skin damage & irritation.  

 

The COVID-19 pandemic has its contribution in the need to consider the aspects of dermatologic care. For example, adjustment of the approach to im/m medications, phototherapy, skin cancer medications, in addition to the routine clinical care. The impact of immunosuppressive therapy (im/m) for dermatologic lesions on risk for developing SARS-CoV-2 infection and risk for COVID-19 sequela still uncertain. The decision to continue or to commence im/m therapy for dermatologic disease during pandemic era should be currently individualized. Examples of important factors to consider include the ptn's infectious state, the im/m under consideration, and the impact of therapy cessation on the dermatologic diseases and other co-morbidities. In view of the lack of evidence indicating benefit of im/m withdrawal in ptns without COVID-19, continuation of im/m agents for dermatologic disease can be considered a safe & appropriate option in this cohort. The option to commence a new im/m agent should include careful consideration of potential risk & benefit of therapy. In ptns with risk for severe COVID-19 disease, it may be wise to defer im/m agents in favor of other therapies.  

 

Infection activity is a crucial indication for withdrawal & avoidance of start of im/m agents, and some professional institutes, including the American Academy of Dermatology, have provided statements that recommend withdrawal of im/m drugs for skin disease in ptns developing COVID-19 infection. In view of the paucity of evidence on risks & benefits of discontinuation, our decision to continue or discontinue an im/m agent in ptns with presumed/confirmed COVID-19 infection may be proceeded on an individualized basis. If withdrawn, an im/m agent may be resumed with documented complete recovery form COVID-19. The COVID-19 pandemic has contributed to prevalent use of telemedicine for routine patients’ care. With in-person visit, the appropriate infection control measures should be undertaken.

 

REFERENCES

  1. Freeman EE, McMahon DE. Creating dermatology guidelines for COVID-19: The pitfalls of applying evidence-based medicine to an emerging infectious disease. J Am Acad Dermatol 2020; 82:e231.
  2. Galván Casas C, Català A, Carretero Hernández G, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol 2020; 183:71.
  3. de Masson A, Bouaziz JD, Sulimovic L, et al. Chilblains is a common cutaneous finding during the COVID-19 pandemic: A retrospective nationwide study from France. J Am Acad Dermatol 2020; 83:667.
  4. Freeman EE, McMahon DE, Lipoff JB, et al. Pernio-like skin lesions associated with COVID-19: A case series of 318 patients from 8 countries. J Am Acad Dermatol 2020; 83:486.
  5. Daneshgaran G, Dubin DP, Gould DJ. Cutaneous Manifestations of COVID-19: An Evidence-Based Review. Am J Clin Dermatol 2020; 21:627.
  6. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020; 382:1708.
  7. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol 2020; 34:e212.
  8. Madigan LM, Micheletti RG, Shinkai K. How Dermatologists Can Learn and Contribute at the Leading Edge of the COVID-19 Global Pandemic. JAMA Dermatol 2020; 156:733.
  9. Suchonwanit P, Leerunyakul K, Kositkuljorn C. Cutaneous manifestations in COVID-19: Lessons learned from current evidence. J Am Acad Dermatol 2020; 83:e57.
  10. Türsen Ü, Türsen B, Lotti T. Cutaneous sıde-effects of the potential COVID-19 drugs. Dermatol Ther 2020; 33:e13476.
  11. Freeman EE, McMahon DE, Fitzgerald ME, et al. The American Academy of Dermatology COVID-19 registry: Crowdsourcing dermatology in the age of COVID-19. J Am Acad Dermatol 2020; 83:509.
  12. Freeman EE, McMahon DE, Lipoff JB, et al. The spectrum of COVID-19-associated dermatologic manifestations: An international registry of 716 patients from 31 countries. J Am Acad Dermatol 2020; 83:1118.

 

COMMENTS

Name

Hemodialysis,21,My Publications,2,Peritoneal dialysis,14,Prevention of renal failure,61,Renal face,43,Renal Transplantation,49,TOP RECENT,37,
ltr
item
fedo: Cutaneous manifestations & Dermatologic care IN COVID-19
Cutaneous manifestations & Dermatologic care IN COVID-19
Cutaneous manifestations & Dermatologic care IN COVID-19
https://lh3.googleusercontent.com/-gbMVc2rr9gQ/X7N_m7MVxFI/AAAAAAAAAdM/Y9sQRP3zRtcEEikoUqwHecPu1bh-v1jwQCLcBGAsYHQ/w320-h276/image.png
https://lh3.googleusercontent.com/-gbMVc2rr9gQ/X7N_m7MVxFI/AAAAAAAAAdM/Y9sQRP3zRtcEEikoUqwHecPu1bh-v1jwQCLcBGAsYHQ/s72-w320-c-h276/image.png
fedo
https://www.fedokidney.com/2020/11/cutaneous-manifestations-dermatologic.html
https://www.fedokidney.com/
https://www.fedokidney.com/
https://www.fedokidney.com/2020/11/cutaneous-manifestations-dermatologic.html
true
8610857019469578230
UTF-8
Loaded All Posts Not found any posts VIEW ALL Readmore Reply Cancel reply Delete By Home PAGES POSTS View All RECOMMENDED FOR YOU LABEL ARCHIVE SEARCH ALL POSTS Not found any post match with your request Back Home Sunday Monday Tuesday Wednesday Thursday Friday Saturday Sun Mon Tue Wed Thu Fri Sat January February March April May June July August September October November December Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec just now 1 minute ago $$1$$ minutes ago 1 hour ago $$1$$ hours ago Yesterday $$1$$ days ago $$1$$ weeks ago more than 5 weeks ago Followers Follow THIS PREMIUM CONTENT IS LOCKED STEP 1: Share to a social network STEP 2: Click the link on your social network Copy All Code Select All Code All codes were copied to your clipboard Can not copy the codes / texts, please press [CTRL]+[C] (or CMD+C with Mac) to copy Table of Content